Three, six, or twelve months of dual antiplatelet therapy after des implantation in patients with or without acute coronary syndromes: An individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients

European Heart Journal

Volumn 38, Issue 14, 2017, Pages 1034-1043

  Palmerini, Tullio ^a   Della Riva, Diego ^a   Benedetto, Umberto ^b   Reggiani, Bletizia Bacchi ^a   Feres, Fausto ^c   Abizaid, Alexandre ^c   Gilard, Martine ^d   Morice, Marie Claude ^e   Valgimigli, Marco ^f   Hong, Myeong Ki ^g   Kim, Byeong Keuk ^g   Jang, Yangsoo ^g   Kim, Hyo Soo ^h   Park, Kyung Woo ^h   Colombo, Antonio ⁱ   Chieffo, Alaide ⁱ   Sangiorgi, Diego ^a   Biondi Zoccai, Giuseppe ^j,k   Généreux, Philippe ^l   Angelini, Gianni D ^b   Pufulete, Maria ^b   White, Jonathon ^l   Bhatt, Deepak L ^m   Stone, Gregg W ^l   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Dante Pazzanese Hospital   (Brazil)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^f BERN UNIVERSITY HOSPITAL   (Switzerland)

^g Yonsei University College of Medicine   (South Korea)

^h Seoul National University Hospital   (South Korea)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k IRCCS NEUROMED   (Italy)

^l Department of Medicine   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Drug eluting stent; Dual antiplatelet therapy; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COCHRANE LIBRARY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; EMBASE; HEART INFARCTION; HUMAN; MEDLINE; META ANALYSIS; NETWORK META-ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLEEDING; BLOOD VESSEL TRANSPLANTATION; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DRUG ADMINISTRATION; FEMALE; GRAFT OCCLUSION, VASCULAR; HEART MUSCLE REVASCULARIZATION; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANALYSIS OF VARIANCE; ASPIRIN; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ARTERY DISEASE; DEATH, SUDDEN, CARDIAC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 85015053064     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw627     Document Type: Article

References (26)

1. Palmerini T, Stone GW. Optimal duration of dual antiplatelet therapy after drugeluting stent implantation: conceptual evolution basedon emerging evidence. Eur Heart J 2016;37:353-364.
2. Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys PW. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2009;2:534-541.
3. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313:1657-1665.
4. Royston P, Lambert P. Flexible Parametric Survival Analysis Using STATA: Beyond the Cox Model. College Station, Texas: STATA PRESS; 2011.
5. Klein J, Moeschberger M, Survival Analysis. Techniques for censored and truncated data. 2nd ed. New York: Springer Publishers; 2003.
6. Biondi-Zoccai G. Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison. Hauppauge, NY: Nova Science Publishers; 2014.
7. Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 2014;64:2086-2097.
8. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB III, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013;310:2510-2522.
9. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Lyuycx-Bore A, Gommeaux A, Cassat C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, Morice MC. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 2014;65:777-786.
10. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, ChungWY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Sixmonth versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 2012;125:505-513.
11. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimuseluting stent implantation). J Am Coll Cardiol 2012;60:1340-1348.
12. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fuca G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012;125:2015-2026.
13. Schulz-Schupke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015;36:1252-1263.
14. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'gara PT, Sabatine MS, Smith PK, Smith SC. Jr., 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American college of Cardiology/American heart association task forceon clinical practice guidelines. J Am Coll Cardiol 2016;68:1082-1115.
15. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Forceon Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
16. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent STSegment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
17. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
18. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-1402.
19. Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107:966-972.
20. Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J 2004;25:720-722.
21. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelveor 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-2166.
22. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015;65:2211-2221.
23. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:2556-2566.
24. Capodanno D, Gargiulo G, Buccheri S, Giacoppo D, Capranzano P, Tamburino C. Meta-analyses of dual antiplatelet therapy following drug-eluting stent implantation: do bleeding and stent thrombosis weigh similaron mortality? J Am Coll Cardiol 2015;66:1639-1640.
25. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800.
26. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 2015;37:390-399.